The Chen-Huang Center for EGFR-Mutant Lung Cancers aims to advance care and research of EGFR-mutant lung cancer with clinical trials of new and novel therapies supported by lab research and studies of cancer genetics.
Our trials include studies for patients with newly diagnosed EGFR-mutant lung cancer and patients whose cancer has advanced on current therapy, in addition to studies of cancer genetics.
A patient must meet certain requirements to participate in a clinical trial. Your doctor or another member of your health care team is the best resource for knowing your treatment options and eligibility.
EGFR Inhibitor Naïve
For patients that are newly diagnosed or have not yet started treatment for EGFR-mutant lung cancer:
- 22-331 – A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
- 21-565 – A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)
- 20-601 – Phase I Trial of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib
- 18-070 – Phase II study of osimertinib with on-study and post-progression biopsies
EGFR Inhibitor Resistant
For patients that have had their EGFR-mutant lung cancer treated with targeted therapy already and have developed disease progression or relapse:
- 22-491 -- A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients with Active Epidermal Growth Factor Receptor Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer
- 21-249 – Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1 Inhibitor
- 21-222 – A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
- 20-601 – Phase I Trial of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib
